BioLineRx Ltd.
Business
BioLineRx is a biopharmaceutical company developing therapies in oncology and rare diseases. Its lead product APHEXDA (motixafortide), a CXCR4 antagonist peptide approved for stem-cell mobilization in multiple myeloma, is commercialized by partners Ayrmid and Gloria in their respective territories. The company advances GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma, through a joint venture with Hemispherian, and maintains legacy product BL-5010 for skin-lesion removal, out-licensed to Perrigo. Operations span multiple geographies through out-licensing partnerships in Asia and globally outside Asia.
Summary from 20-F filed 2026-03-23
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-2.03M |
| Total assets | $40.91M |
| Total liabilities | $17.56M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is BioLineRx Ltd.'s CIK number?
BioLineRx Ltd.'s SEC CIK number is 0001498403 (1498403). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find BioLineRx Ltd.'s SEC filings?
All of BioLineRx Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.